Beijing WestVac Biopharma

WestVac Biopharma is a clinical-stage biotechnology company specializing in the development and manufacturing of innovative vaccines and immunotherapy treatments. Founded by scientists from Sichuan University, the company utilizes advanced platforms such as insect cell expression systems and mRNA technology to address infectious diseases and oncology. Its lead product, a recombinant COVID-19 vaccine (Coviccin), was among the first of its kind to receive emergency use authorization in China. WestVac maintains large-scale GMP manufacturing facilities and continues to expand its pipeline into areas like influenza, rabies, and tumor vaccines. The company has secured significant funding from prominent global investors to support its rapid growth and international expansion.